These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36222846)

  • 21. Dysregulation of the Keap1-Nrf2 pathway in cancer.
    Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
    Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin increases the radiosensitivity of non-small cell lung cancer cells by destabilizing NRF2.
    Sun X; Dong M; Gao Y; Wang Y; Du L; Liu Y; Wang Q; Ji K; He N; Wang J; Zhang M; Gu Y; Song H; Zhai H; Feng L; Xu C; Liu Q
    Biochem Pharmacol; 2022 May; 199():114981. PubMed ID: 35227644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers.
    Koppula P; Lei G; Zhang Y; Yan Y; Mao C; Kondiparthi L; Shi J; Liu X; Horbath A; Das M; Li W; Poyurovsky MV; Olszewski K; Gan B
    Nat Commun; 2022 Apr; 13(1):2206. PubMed ID: 35459868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
    Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
    Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Binkley MS; Jeon YJ; Nesselbush M; Moding EJ; Nabet BY; Almanza D; Kunder C; Stehr H; Yoo CH; Rhee S; Xiang M; Chabon JJ; Hamilton E; Kurtz DM; Gojenola L; Owen SG; Ko RB; Shin JH; Maxim PG; Lui NS; Backhus LM; Berry MF; Shrager JB; Ramchandran KJ; Padda SK; Das M; Neal JW; Wakelee HA; Alizadeh AA; Loo BW; Diehn M
    Cancer Discov; 2020 Dec; 10(12):1826-1841. PubMed ID: 33071215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrative radiogenomic profiling of squamous cell lung cancer.
    Abazeed ME; Adams DJ; Hurov KE; Tamayo P; Creighton CJ; Sonkin D; Giacomelli AO; Du C; Fries DF; Wong KK; Mesirov JP; Loeffler JS; Schreiber SL; Hammerman PS; Meyerson M
    Cancer Res; 2013 Oct; 73(20):6289-98. PubMed ID: 23980093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing.
    Falchetti M; Delgobo M; Zancanaro H; Almeida K; das Neves RN; Dos Santos B; Stefanes NM; Bishop A; Santos-Silva MC; Zanotto-Filho A
    Comput Biol Med; 2023 Jan; 152():106347. PubMed ID: 36493734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. p62-Dependent Phase Separation of Patient-Derived KEAP1 Mutations and NRF2.
    Cloer EW; Siesser PF; Cousins EM; Goldfarb D; Mowrey DD; Harrison JS; Weir SJ; Dokholyan NV; Major MB
    Mol Cell Biol; 2018 Nov; 38(22):. PubMed ID: 30126895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
    Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
    J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
    Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
    Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.
    Mok TSK; Lopes G; Cho BC; Kowalski DM; Kasahara K; Wu YL; de Castro G; Turna HZ; Cristescu R; Aurora-Garg D; Loboda A; Lunceford J; Kobie J; Ayers M; Pietanza MC; Piperdi B; Herbst RS
    Ann Oncol; 2023 Apr; 34(4):377-388. PubMed ID: 36709038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of KEAP1 Silencing on the Regulation of NRF2 Activity in Neuroendocrine Lung Tumors.
    Sparaneo A; Fabrizio FP; la Torre A; Graziano P; Di Maio M; Fontana A; Bisceglia M; Rossi A; Pizzolitto S; De Maglio G; Tancredi A; Grimaldi F; Balsamo T; Centra F; Manzorra MC; Trombetta D; Pantalone A; Bonfitto A; Maiello E; Fazio VM; Muscarella LA
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel.
    Yan K; Niu L; Wu B; He C; Deng L; Chen C; Lan Z; Lin C; Kuang W; Lin H; Zou J; Zhang W; Luo Z
    Ann Med; 2023; 55(2):2280708. PubMed ID: 37967237
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    Nabeshima T; Hamada S; Taguchi K; Tanaka Y; Matsumoto R; Yamamoto M; Masamune A
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G419-G427. PubMed ID: 31961719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses.
    Lee S; Lim MJ; Kim MH; Yu CH; Yun YS; Ahn J; Song JY
    Free Radic Biol Med; 2012 Aug; 53(4):807-16. PubMed ID: 22684019
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Emmanuel N; Li H; Chen J; Zhang Y
    Oncotarget; 2022 Oct; 13():1136-1139. PubMed ID: 36264074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
    Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
    Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC.
    Hellyer JA; Padda SK; Diehn M; Wakelee HA
    J Thorac Oncol; 2021 Mar; 16(3):395-403. PubMed ID: 33307193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.